Dr. Kevin Pan is a co-founder of Asieris Pharmaceuticals and has served as chairman of the board and CEO since Mach 2010. Asieris is a private, VC-backed clinical-stage biotech company based in China and with clinical operations in the US. Before founding Asieris, Dr. Pan was a founding member of Hutchison MediPharma, a leading Chinese biopharmaceutical company listed on AIM and Nasdaq. He served as the senior director of drug discovery chemistry and IP at the beginning, and then led the company’s business development with a successful track record of partnership deals with P&G and Merck Serono. Dr. Pan started his career in the pharmaceutical industry from the R&D divisions at Pfizer (Groton, CT) and Johnson & Johnson (Spring House, PA).  Dr. Pan received a BS degree in organic chemistry from Fudan University in Shanghai and a Ph.D. degree in bioorganic chemistry from Rutgers, the State University of New Jersey. He had been an adjunct professor at the School of Pharmacy of Jilin University in China between 2005-2010, and he is currently members of the Bayhelix Group and Chinese Society of Clinical Oncology (CSCO).